Eli Lilly terminated the remainder of its RIPK1 partnership with Rigel Pharmaceuticals, following an earlier pullback from a CNS-focused portion of the alliance. The latest move is framed as part of a broader disengagement from the RIPK1 target area as Lilly reallocates priorities. The decision ends access for Lilly to a set of early and mid-stage RIPK1 programs tied to the broader agreement, while Rigel faces the challenge of re-banding its development plans and funding strategy. For the target landscape, the exit adds to evidence that RIPK1 inhibitors remain difficult for large drugmakers to sustain through late-stage risk, shifting attention to competing mechanisms and validated pathways.